Vistagen Therapeutics (VTGN) Accumulated Expenses (2017 - 2025)
Historic Accumulated Expenses for Vistagen Therapeutics (VTGN) over the last 12 years, with Q4 2025 value amounting to $9.3 million.
- Vistagen Therapeutics' Accumulated Expenses rose 6920.83% to $9.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $9.3 million, marking a year-over-year increase of 6920.83%. This contributed to the annual value of $8.8 million for FY2025, which is 29418.34% up from last year.
- Per Vistagen Therapeutics' latest filing, its Accumulated Expenses stood at $9.3 million for Q4 2025, which was up 6920.83% from $8.4 million recorded in Q3 2025.
- Over the past 5 years, Vistagen Therapeutics' Accumulated Expenses peaked at $9.3 million during Q4 2025, and registered a low of $129300.0 during Q4 2023.
- Moreover, its 5-year median value for Accumulated Expenses was $2.2 million (2021), whereas its average is $3.1 million.
- Its Accumulated Expenses has fluctuated over the past 5 years, first crashed by 8808.51% in 2023, then surged by 412969.84% in 2024.
- Over the past 5 years, Vistagen Therapeutics' Accumulated Expenses (Quarter) stood at $2.6 million in 2021, then plummeted by 58.7% to $1.1 million in 2022, then plummeted by 88.09% to $129300.0 in 2023, then surged by 4129.7% to $5.5 million in 2024, then soared by 69.21% to $9.3 million in 2025.
- Its Accumulated Expenses was $9.3 million in Q4 2025, compared to $8.4 million in Q3 2025 and $6.6 million in Q2 2025.